SUCCESSOR-1: This study is comparing two different combinations of drugs to determine which is more safe and effective in treating people with relapsed or refractory multiple myeloma who have had prior treatmentA Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)

Inclusion

• Participant has documented diagnosis of MM and measurable disease, defined as any of the following:

  • M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or
  • M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP)
  • For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio.
• Participants received 1 to 3 prior lines of antimyeloma therapy.
• Participants achieved minimal response [MR] or better to at least 1 prior antimyeloma therapy.